Human leukocyte antigen supertype matching after myeloablative hematopoietic cell transplantation with 7/8 matched unrelated donor allografts: a report from the Center for International Blood and Marrow Transplant Research.

Published

Journal Article

The diversity of the human leukocyte antigen (HLA) class I and II alleles can be simplified by consolidating them into fewer supertypes based on functional or predicted structural similarities in epitope-binding grooves of HLA molecules. We studied the impact of matched and mismatched HLA-A (265 versus 429), -B (230 versus 92), -C (365 versus 349), and -DRB1 (153 versus 51) supertypes on clinical outcomes of 1934 patients with acute leukemias or myelodysplasia/myeloproliferative disorders. All patients were reported to the Center for International Blood and Marrow Transplant Research following single-allele mismatched unrelated donor myeloablative conditioning hematopoietic cell transplantation. Single mismatched alleles were categorized into six HLA-A (A01, A01A03, A01A24, A02, A03, A24), six HLA-B (B07, B08, B27, B44, B58, B62), two HLA-C (C1, C2), and five HLA-DRB1 (DR1, DR3, DR4, DR5, DR9) supertypes. Supertype B mismatch was associated with increased risk of grade II-IV acute graft-versus-host disease (hazard ratio =1.78, P=0.0025) compared to supertype B match. Supertype B07-B44 mismatch was associated with a higher incidence of both grade II-IV (hazard ratio=3.11, P=0.002) and III-IV (hazard ratio=3.15, P=0.01) acute graft-versus-host disease. No significant associations were detected between supertype-matched versus -mismatched groups at other HLA loci. These data suggest that avoiding HLA-B supertype mismatches can mitigate the risk of grade II-IV acute graft-versus-host disease in 7/8-mismatched unrelated donor hematopoietic cell transplantation when multiple HLA-B supertype-matched donors are available. Future studies are needed to define the mechanisms by which supertype mismatching affects outcomes after alternative donor hematopoietic cell transplantation.

Full Text

Duke Authors

Cited Authors

  • Lazaryan, A; Wang, T; Spellman, SR; Wang, H-L; Pidala, J; Nishihori, T; Askar, M; Olsson, R; Oudshoorn, M; Abdel-Azim, H; Yong, A; Gandhi, M; Dandoy, C; Savani, B; Hale, G; Page, K; Bitan, M; Reshef, R; Drobyski, W; Marsh, SG; Schultz, K; Müller, CR; Fernandez-Viña, MA; Verneris, MR; Horowitz, MM; Arora, M; Weisdorf, DJ; Lee, SJ

Published Date

  • October 2016

Published In

Volume / Issue

  • 101 / 10

Start / End Page

  • 1267 - 1274

PubMed ID

  • 27247320

Pubmed Central ID

  • 27247320

Electronic International Standard Serial Number (EISSN)

  • 1592-8721

Digital Object Identifier (DOI)

  • 10.3324/haematol.2016.143271

Language

  • eng

Conference Location

  • Italy